Director, Institute for Clinical Research (ICR)

Public Health Medicine Specialist

Email: sheamini@crc.gov.my

M.MedPH (NUS), MBBS (UM)

Areas of interest: Clinical Outcome, Healthcare Facility Survey, Health System, Primary Care

Awards and achievements:

• COVID-19 International Innovation Award (Gold award) - 2022
• International Federation of Inventors Association (IFIA) Innovation in Data Practices for COVID -19 Vaccine Effectiveness Research (The RECoVaM Study Group) (Special award) - 2022
• Awarded the MOH's Advanced Competency Programme for Senior Officers - 2016
• Selected by MOH to attend the Capacity Building program (CAP) on Universal Health Coverage (UHC) Exchange and Study Program on UHC Monitoring and Evaluation organised by the Joint Learning Network ( JLN) - 2013
• WHO fellowship on Health Economics that was held in the University of York (12-22nd June 2007)

Dr. Sheamini Sivasampu is currently serving as the Director of the Institute for Clinical Research at the National Institutes for Health since May 2023. Her illustrious career spans several pivotal roles, reflecting her expertise and commitment to advancing clinical and public health research.

Before assuming her current position, she was the Head of the Centre for Clinical Outcomes Research, where she led groundbreaking initiatives in evaluating healthcare outcomes. Prior to that, she served as Deputy Director of the National Clinical Research Centre and held the role of Visiting Scientist at the Harvard TH Chan School of Public Health. Throughout her career, she has been instrumental in shaping national and international healthcare policies. She serves as the Chairperson of the Technical Working Group for COVID-19 Vaccines and played key roles in various committees such as the National COVID-19 Immunisation Guidelines Committee – RECoVaM. Refer link for more details: https://linktr.ee/recovamys 

Her expertise extends to health technology assessment and evidence-based medicine, highlighted by her tenure in the Health Technology Assessment Section of the Medical Development Division Hospital Division. She has been a pivotal figure in developing clinical practice guidelines and ensuring their effective implementation across Malaysia. Dr. Sheamini has been actively involved in global health initiatives, representing Malaysia at prestigious forums such as the WHO Clinical Trial Forum and serving as the Malaysian Health System Research collaborative project lead with Harvard TH Chan School of Public Health.

Impact evaluation of guidelines on antibiotic utilisation & appropriateness in Malaysian public primary care: an interrupted time series analysis.

Identifying factors in the provision of intravenous stroke thrombolysis in Malaysia: a multiple case study from the healthcare providers' perspective.

Post COVID-19 condition among adults in Malaysia following the Omicron wave: A prospective cohort study. 

A comparison between antibiotic utilisation in public and private community healthcare in Malaysia.

Antiplatelet Therapy for Secondary Prevention in Patients with Ischaemic Stroke and Transient Ischaemic Attack: A Retrospective Cohort Study in Malaysia. 

Thrombocytopenia and venous thromboembolic events after BNT162b2, CoronaVac, ChAdOx1 vaccines and SARS-CoV-2 infection: a self-controlled case series study.

Expert review on global real-world vaccine effectiveness against SARS-CoV-2

A systematic review of the relationship between household food insecurity and childhood undernutrition.

Myocarditis/pericarditis following vaccination with BNT162b2, CoronaVac, and ChAdOx1 among adolescent and adult in Malaysia

The Effectiveness of Enhanced Primary Healthcare (EnPHC) interventions on Type 2 diabetes management in Malaysia: Difference-in-differences (DID) analysis.